Luye Pharma Group (2186) Stock Statistics & Valuation Metrics

Luye Pharma Group has a market cap or net worth of HK$7.98B. The enterprise value is HK$11.71B.

Luye Pharma Group has 3,994,515,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Luye Pharma Group’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 3.13%.

The current PE Ratio of Luye Pharma Group is 11.5. Luye Pharma Group’s PEG ratio is 0.67.

In the last 12 months, Luye Pharma Group had revenue of 6.31B and earned 618.75M in profits. Earnings per share was 0.16.

In the last 12 months, operating cash flow was 2.12B and capital expenditures -567.28M, giving a free cash flow of 1.56B billion.

Luye Pharma Group pays an annual dividend of HK$0.06, resulting in a dividend yield of ―

Luye Pharma Group upcoming earnings date is Aug 27, 2026, TBA (Confirmed).

Luye Pharma Group as a current ratio of 1.53, with Debt / Equity ratio of 58.59%

In the past 12 months, Luye Pharma Group has paid 238.98M in taxes.

Luye Pharma Group EV to EBITDA ratio is 7.20, with an EV/FCF ratio of 18.59.

Luye Pharma Group has HK$8.88B in cash and marketable securities with HK$9.42B in debt, giving a net cash position of -HK$541.73M billion.

Gross margin is 65.99%, with operating margin of 19.70%, and net profit margin of 9.81%.

The average price target for Luye Pharma Group is HK$4.22, which is 11.43% higher than the current price. The consensus rating is Moderate Buy